773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 773,148 shares of the company’s stock, valued at approximately $20,991,000. Pictet Asset Management Holding SA owned about 1.43% of Upstream Bio at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Upstream Bio by 12.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock worth $45,944,000 after acquiring an additional 271,718 shares during the last quarter. UBS Group AG grew its holdings in shares of Upstream Bio by 563.4% during the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after purchasing an additional 1,533,972 shares during the last quarter. Marshall Wace LLP raised its position in Upstream Bio by 198.8% in the 3rd quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock worth $16,327,000 after purchasing an additional 577,473 shares during the period. Parkman Healthcare Partners LLC lifted its stake in Upstream Bio by 17.9% in the third quarter. Parkman Healthcare Partners LLC now owns 843,502 shares of the company’s stock worth $15,866,000 after purchasing an additional 127,998 shares during the last quarter. Finally, Woodline Partners LP lifted its stake in Upstream Bio by 7.9% in the third quarter. Woodline Partners LP now owns 602,252 shares of the company’s stock worth $11,328,000 after purchasing an additional 44,000 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target for the company. in a research report on Friday, March 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Upstream Bio presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Upstream Bio Stock Up 2.4%

Shares of UPB opened at $9.40 on Friday. The stock has a market capitalization of $511.55 million, a P/E ratio of -3.52 and a beta of 1.29. Upstream Bio, Inc. has a twelve month low of $7.25 and a twelve month high of $33.68. The firm has a fifty day simple moving average of $9.03 and a two-hundred day simple moving average of $20.00.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. Sell-side analysts expect that Upstream Bio, Inc. will post -3.02 EPS for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.